Lymphoma Clinical Trials in Cleveland

Showing 241-260 of 316 trials

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

NCT00354926

This study is designed to provide evidence of the safety and a preliminary understanding of the efficacy of AME 133v.

Applied Molecular Evolution67 participantsStarted Jul 2006

Birmingham, Alabama, United States • Los Angeles, California, United States • Stanford, California, United States +8 more locations

TERMINATEDPHASE1< 1 mile

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

NCT00671112

RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with bortezomib in treating patients with relapsed or refractory lymphoma.

714leukemiaLymphoma

Brian Hill, MD, PhD30 participantsStarted Jun 2008

Cleveland, Ohio, United States

COMPLETEDPHASE251 miles

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

NCT01403636

Primary Objective: \- To evaluate the efficacy of SAR245409 as determined by the objective response rate (ORR) in patients with 1 of following relapsed or refractory lymphoma or leukemia subtypes: mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or diffuse large B cell lymphoma (DLBCL) Secondary Objectives: * To assess duration of response, progression free survival (PFS), and proportion of patients with PFS at 6 months (24 weeks) in patients with either MCL, FL, CLL/SLL or DLBCL treated with SAR245409 * To evaluate the safety and tolerability of SAR245409 in patients with MCL, FL, CLL/SLL or DLBCL * To further characterize the plasma pharmacokinetics (PK) of SAR245409 in patients with MCL, FL, CLL/SLL or DLBCL

Lymphoma

Sanofi167 participantsStarted Oct 2011

Los Angeles, California, United States • Fort Meyers, Florida, United States • Augusta, Georgia, United States +27 more locations

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Lymphoma Trials in Other Cities

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Imexon for Relapsed Follicular and Aggressive Lymphomas

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Other Conditions in Cleveland